Treatment News : FDA OKs Generic Truvada for Use Abroad

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 5, 2013

FDA OKs Generic Truvada for Use Abroad

The U.S. Food and Drug Administration (FDA) has approved a generic version of Gilead Sciences’ HIV antiretroviral Truvada for use outside the United States. Strides Arcolab Limited of Bangalore, India, will manufacture tablets made of emtricitabine and tenofovir disoproxil fumarate, the two meds found in Truvada. The drugs received an expedited review process thanks to the President’s Emergency Plan for AIDS Relief (PEPFAR).

Patent protection forbids the current sale of generic Truvada within the United States, but this approval by the FDA, given because the two generic drugs meet all required quality, safety and efficacy standards, green-lights their use in the resource-poor nations that PEPFAR serves. Considering the World Health Organization’s shift in treatment guidelines—it raised the CD4 threshold for beginning therapy from 350 CD4 cells to 500—the approval of a less expensive version of Truvada is an important cost-savings measure.

To read the FDA release, click here.

Search: U.S. Food and Drug Administration, FDA, Gilead Sciences, Truvada, emtricitabine, tenofovir disoproxil fumarate, Strides Arcolab Limited, PEPFAR, World Health Organization.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    juliar33
    brooklyn
    New York


    hollywoodvers1
    Los Angeles
    California


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.